Surrozen (SRZN) Non Operating Investment Income (2020 - 2023)
Surrozen (SRZN) recorded quarterly Non Operating Investment Income of -$1000.0 in Q4 2023, up 75.0% quarter-over-quarter from -$4000.0 in Q3 2023, and down 100.55% on a YoY basis from $183000.0 in Q4 2022.
Surrozen (SRZN) Non Operating Investment Income (2020 - 2023) Analysis & Trends
Surrozen's Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$1000.0 for Q4 2023.
- In Q4 2023, Non Operating Investment Income fell 100.55% year-over-year to -$1000.0; the TTM figure through Sep 2024 stood at -$1000.0 (down 100.24% YoY), while the FY2023 annual figure was $241000.0, up 297.54% from the prior year.
- Non Operating Investment Income was -$1000.0 for Q4 2023 at Surrozen, up from -$4000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $191000.0 in Q1 2023 to a low of -$310000.0 in Q1 2022.
- Historically, Non Operating Investment Income has averaged -$762.82 across 4 years, with a median of -$4000.0 in 2023.
- The sharpest annual moves came in 2021 and 2022: Non Operating Investment Income slumped 1127.51% in 2021, then surged 425.0% in 2022.
- A 4-year view of Non Operating Investment Income shows it stood at -$8391.0 in 2020, then plunged by 1127.51% to -$103000.0 in 2021, then soared by 277.67% to $183000.0 in 2022, then slumped by 100.55% to -$1000.0 in 2023.
- The last three Non Operating Investment Income figures came in at -$1000.0 (Q4 2023), -$4000.0 (Q3 2023), and $55000.0 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Op. Investment Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 230,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | 55,000.00 |
| Jun 30, 2023 | 55,000.00 |
| Mar 31, 2023 | 191,000.00 |
| Mar 31, 2023 | 191,000.00 |
| Dec 31, 2022 | 183,000.00 |
| Dec 31, 2022 | 183,000.00 |
| Sep 30, 2022 | 52,000.00 |
| Sep 30, 2022 | 52,000.00 |
| Jun 30, 2022 | -47,000.00 |
| Jun 30, 2022 | -47,000.00 |
| Mar 31, 2022 | -310,000.00 |
| Mar 31, 2022 | -310,000.00 |
| Dec 31, 2021 | -103,000.00 |
| Dec 31, 2021 | -103,000.00 |
| Sep 30, 2021 | -16,000.00 |
| Sep 30, 2021 | -16,000.00 |